Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:11 AM EDTClear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "OCUL is trading down (-6%, XBI +/- 0%) after reporting 2Q25 earnings. Revenue was roughly in line ($13.5M vs $13.6M) and expenses outpaced expectations ($51.1M vs $43.1M). But we believe the weakness today is caused by the disclosure that the company tapped into its ATM for $97M in... More
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:07 AM EDTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "Tuesday, before market open, Ocular Therapeutix reported 2Q25 financial results. Management hosted a call to discuss recent progress and outlook for the remainder of 2025. The company reported $13.5M in total revenue vs. our estimated $12.0M and diluted EPS of $(0.39) vs. our... More
